The cancer therapy developer, which is commercialising research from University of Texas, has raised series B1 and B2 financing.

Immune-Onc Therapeutics, a US-based immuno-oncology therapy developer drawing on research from University of Texas, announced on Tuesday it has secured $73m in series B1 and B2 funding.
Investment management firm Oceanpine Capital led the round and was joined by Octagon Capital, Sphera Healthcare, Northern Light Venture Capital, Vivo Capital and Leukemia & Lymphoma Society’s Therapy Acceleration Program.
Founded in 2015, Immune-Onc is developing cancer immunotherapies intended to inhibit the infiltration of tumours and disrupt the suppression of patients’…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?